NASDAQ:KNSA Kiniksa Pharmaceuticals (KNSA) Stock Price, News & Analysis → The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (From Smallcaps Daily) (Ad) Free KNSA Stock Alerts $20.26 -0.07 (-0.34%) (As of 05/8/2024 ET) Add Compare Share Share Today's Range$20.02▼$20.3850-Day Range$16.88▼$21.7452-Week Range$13.02▼$22.09Volume272,503 shsAverage Volume404,867 shsMarket Capitalization$1.44 billionP/E Ratio184.20Dividend YieldN/APrice Target$31.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Kiniksa Pharmaceuticals alerts: Email Address Kiniksa Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside53.0% Upside$31.00 Price TargetShort InterestBearish5.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.55Based on 6 Articles This WeekInsider TradingSelling Shares$709,929 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.10) to $0.39 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.51 out of 5 starsMedical Sector445th out of 905 stocksPharmaceutical Preparations Industry202nd out of 422 stocks 3.5 Analyst's Opinion Consensus RatingKiniksa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKiniksa Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Kiniksa Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.13% of the outstanding shares of Kiniksa Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverKiniksa Pharmaceuticals has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Kiniksa Pharmaceuticals has recently increased by 13.40%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKiniksa Pharmaceuticals does not currently pay a dividend.Dividend GrowthKiniksa Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KNSA. Previous Next 3.1 News and Social Media Coverage News SentimentKiniksa Pharmaceuticals has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.37 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Kiniksa Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for KNSA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows3 people have added Kiniksa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kiniksa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $709,929.00 in company stock.Percentage Held by Insiders54.57% of the stock of Kiniksa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.95% of the stock of Kiniksa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kiniksa Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kiniksa Pharmaceuticals are expected to grow in the coming year, from ($0.10) to $0.39 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kiniksa Pharmaceuticals is 184.20, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 141.48.Price to Earnings Ratio vs. SectorThe P/E ratio of Kiniksa Pharmaceuticals is 184.20, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 178.55.Price to Book Value per Share RatioKiniksa Pharmaceuticals has a P/B Ratio of 3.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kiniksa Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. About Kiniksa Pharmaceuticals Stock (NASDAQ:KNSA)Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Read More KNSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KNSA Stock News HeadlinesMay 7, 2024 | globenewswire.comKiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care ConferenceMay 7, 2024 | americanbankingnews.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Coverage Initiated by Analysts at Wells Fargo & CompanyMay 8, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.May 4, 2024 | americanbankingnews.comJPMorgan Chase & Co. Boosts Kiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target to $30.00May 4, 2024 | msn.comWells Fargo Initiates Coverage of Kiniksa Pharmaceuticals (KNSA) with Overweight RecommendationApril 26, 2024 | finance.yahoo.comAnalyst Estimates: Here's What Brokers Think Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) After Its First-Quarter ReportApril 25, 2024 | seekingalpha.comKiniksa Pharmaceuticals Ltd. (KNSA) Q1 2024 Earnings Call TranscriptApril 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kiniksa Pharmaceuticals Amid Strong Q1 Performance and Promising Drug ProspectsMay 8, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.April 24, 2024 | markets.businessinsider.comCan Growing Adoption Of Arcalyst Drive KNSA Stock Up?April 24, 2024 | seekingalpha.comKiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take ShapeApril 24, 2024 | finance.yahoo.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call TranscriptApril 24, 2024 | finance.yahoo.comKiniksa Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsApril 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kiniksa Pharmaceuticals Amidst Growth Potential and Strong Commercial ExecutionApril 23, 2024 | seekingalpha.comKiniksa Pharmaceuticals, Ltd. 2024 Q1 - Results - Earnings Call PresentationApril 23, 2024 | msn.comKiniksa Pharmaceuticals reports mixed Q1 results; raises FY24 outlookApril 23, 2024 | markets.businessinsider.comKNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024April 23, 2024 | finance.yahoo.comKiniksa Pharmaceuticals Ltd (KNSA) Q1 2024 Earnings Overview: Surpasses Revenue ForecastsApril 23, 2024 | globenewswire.comKiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio ExecutionApril 20, 2024 | investing.comKiniksa Pharmaceuticals Ltd (KNSA)April 16, 2024 | globenewswire.comKiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024April 2, 2024 | globenewswire.comKiniksa Pharmaceuticals Announces Development Indication for AbiprubartMarch 7, 2024 | msn.com5 Biotech Stocks With 26% Upside Potential or MoreMarch 3, 2024 | investing.comEarnings call: Kiniksa Pharmaceuticals sees robust growth in ARCALYST salesMarch 3, 2024 | wsj.comKiniksa Pharmaceuticals Ltd.March 1, 2024 | seekingalpha.comKiniksa Pharmaceuticals Ltd. (KNSA) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comKiniksa Pharmaceuticals Full Year 2023 Earnings: Beats ExpectationsSee More Headlines Receive KNSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/23/2024Today5/08/2024Next Earnings (Estimated)7/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KNSA CUSIPN/A CIK1730430 Webwww.kiniksa.com Phone(781) 431-9100FaxN/AEmployees297Year FoundedN/APrice Target and Rating Average Stock Price Target$31.00 High Stock Price Target$34.00 Low Stock Price Target$30.00 Potential Upside/Downside+53.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.11 Trailing P/E Ratio184.20 Forward P/E RatioN/A P/E GrowthN/ANet Income$14.08 million Net Margins2.78% Pretax Margin-7.15% Return on Equity-7.26% Return on Assets-6.09% Debt Debt-to-Equity RatioN/A Current Ratio4.21 Quick Ratio3.79 Sales & Book Value Annual Sales$270.26 million Price / Sales5.32 Cash FlowN/A Price / Cash FlowN/A Book Value$6.23 per share Price / Book3.25Miscellaneous Outstanding Shares70,940,000Free Float32,228,000Market Cap$1.44 billion OptionableOptionable Beta0.32 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Sanj K. Patel (Age 55)CEO & Chairman of the Board Comp: $1.44MMr. Eben Tessari (Age 42)Senior VP & COO Comp: $643.75kDr. John F. Paolini (Age 59)Senior VP & Chief Medical Officer Comp: $753.7kMr. Mark Ragosa C.F.A. (Age 50)Senior VP & CFO Mr. Michael R. Megna CPA (Age 53)Chief Accounting Officer & Group VP of Finance Ms. Mei JangSenior VP of Technical OperationsRachel FrankAssociate Director of Investor RelationsMr. Chad MorinSenior VP & Chief Compliance OfficerMs. Madelyn Demsky Zeylikman (Age 50)SVP, General Counsel & Secretary Ms. Melissa MannoSenior VP & Chief Human Resources OfficerMore ExecutivesKey CompetitorsArcus BiosciencesNYSE:RCUSANI PharmaceuticalsNASDAQ:ANIPDay One BiopharmaceuticalsNASDAQ:DAWNXencorNASDAQ:XNCRMorphicNASDAQ:MORFView All CompetitorsInsiders & InstitutionsQRG Capital Management Inc.Sold 832 shares on 5/8/2024Ownership: 0.021%Sei Investments Co.Bought 73,481 shares on 5/7/2024Ownership: 0.104%SG Americas Securities LLCBought 1,435 shares on 5/7/2024Ownership: 0.027%Essex Investment Management Co. LLCBought 850 shares on 5/3/2024Ownership: 0.245%Nordea Investment Management ABBought 126,742 shares on 5/2/2024Ownership: 0.179%View All Insider TransactionsView All Institutional Transactions KNSA Stock Analysis - Frequently Asked Questions Should I buy or sell Kiniksa Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KNSA shares. View KNSA analyst ratings or view top-rated stocks. What is Kiniksa Pharmaceuticals' stock price target for 2024? 4 equities research analysts have issued 12 month price objectives for Kiniksa Pharmaceuticals' shares. Their KNSA share price targets range from $30.00 to $34.00. On average, they anticipate the company's stock price to reach $31.00 in the next twelve months. This suggests a possible upside of 53.0% from the stock's current price. View analysts price targets for KNSA or view top-rated stocks among Wall Street analysts. How have KNSA shares performed in 2024? Kiniksa Pharmaceuticals' stock was trading at $17.54 at the beginning of the year. Since then, KNSA shares have increased by 15.5% and is now trading at $20.26. View the best growth stocks for 2024 here. Are investors shorting Kiniksa Pharmaceuticals? Kiniksa Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,210,000 shares, an increase of 11.8% from the March 15th total of 2,870,000 shares. Based on an average daily volume of 375,600 shares, the short-interest ratio is presently 8.5 days. View Kiniksa Pharmaceuticals' Short Interest. When is Kiniksa Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 23rd 2024. View our KNSA earnings forecast. How were Kiniksa Pharmaceuticals' earnings last quarter? Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) released its quarterly earnings data on Tuesday, April, 23rd. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by $0.11. The business had revenue of $79.90 million for the quarter, compared to analysts' expectations of $76.97 million. Kiniksa Pharmaceuticals had a negative trailing twelve-month return on equity of 7.26% and a net margin of 2.78%. The company's quarterly revenue was up 65.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.18) earnings per share. What ETF holds Kiniksa Pharmaceuticals' stock? Virtus LifeSci Biotech Products ETF holds 22,347 shares of KNSA stock, representing 2.28% of its portfolio. What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO? 1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Kiniksa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD). When did Kiniksa Pharmaceuticals IPO? Kiniksa Pharmaceuticals (KNSA) raised $126 million in an initial public offering on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Kiniksa Pharmaceuticals' major shareholders? Kiniksa Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (0.88%), Peregrine Capital Management LLC (0.33%), Essex Investment Management Co. LLC (0.24%), Hussman Strategic Advisors Inc. (0.22%), Los Angeles Capital Management LLC (0.20%) and Nordea Investment Management AB (0.18%). Insiders that own company stock include Barry D Quart, John F Paolini, Mark Ragosa, Michael R Megna and Sanj K Patel. View institutional ownership trends. How do I buy shares of Kiniksa Pharmaceuticals? Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KNSA) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarningsShocking: One AI startup's revenue could surge 4,735%Manward Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
